A clinical review of epitalon tetrapeptide real-world evidence, including registry data, observational cohorts, and the gap between preclinical telomerase activation and human outcomes.
A clinical review of epitalon tetrapeptide research in special populations including organ transplant recipients, people living with HIV, and other immunocompromised groups. Covers telomerase activation data, safety unknowns, and why no guideline endorses off-label use.
Evidence-based guide to tapering and discontinuing oral estradiol safely, including step-down schedules, symptom rebound management, and when abrupt cessation is appropriate.
Evidence-based guide to food, supplement, and nutrient interactions with oral estradiol. Covers grapefruit, calcium, St. John's wort, and more.
Evidence-based guide to oral estradiol prescribing in patients with liver disease, including Child-Pugh adjustments, first-pass metabolism risks, and when to switch to transdermal delivery.
A physician-level explanation of how oral estradiol works, covering first-pass hepatic metabolism, estrogen receptor binding, genomic and non-genomic signaling, and downstream effects on vasomotor symptoms, bone, and cardiovascular tissue.
What to expect for lab testing, imaging, and exams while taking oral estradiol, and how monitoring for the oral route differs from transdermal estrogen. Written for patient education; requires individualized clinical guidance.
A clinician-grade review of oral estradiol off-label uses, from perimenopausal depression to gender-affirming care, ranked by evidence quality with trial data and guideline citations.
A clinician-grade review of oral estradiol's patent expiration, generic availability, FDA approvals, and what the current market looks like for menopausal hormone therapy.
A guide to oral estradiol safety for young adults aged 18 to 29, covering VTE risk, bone health, fertility, cardiovascular effects, and monitoring protocols.
Compare estradiol-only patch starting doses, strengths and replacement schedules, with a worked label example and checks before discussing dose changes.
Compare the cost of estradiol transdermal patches (Climara, Vivelle-Dot, Minivelle) against oral estradiol, gels, sprays, and vaginal rings. Includes generic pricing, insurance data, and clinical trade-offs.
Who makes estradiol patches? Noven Pharmaceuticals (Miami, FL) makes Vivelle-Dot and Minivelle, Bayer makes Climara in Germany, and Viatris makes Dotti.
Evidence-based monitoring schedule for estradiol transdermal patches, including baseline labs, follow-up intervals, serum estradiol targets, mammography, endometrial surveillance, and bone density screening.
A clinical review of estradiol transdermal patch patent history, current generic availability, and what patients and prescribers should know about branded vs. generic formulations.
Board-reviewed guide to estradiol transdermal patch safety during pregnancy and breastfeeding, including FDA category data, teratogenicity evidence, lactation transfer studies, and clinical alternatives.
A clinical review of real-world evidence from registries, cohort studies, and observational databases on transdermal estradiol patches, including VTE risk, cardiovascular outcomes, and breast cancer data.
Evidence-based guidance on transdermal estradiol patch dosing for patients with chronic kidney disease and renal impairment, including pharmacokinetic considerations, dose adjustments, and monitoring protocols.
Estradiol patches are applied to the skin, not injected. Learn correct placement, rotation sites, adhesion tips, and how transdermal estradiol delivers hormone therapy through the skin.
Find out whether TRICARE covers the estradiol patch for menopausal symptoms, what formulary tier it sits on, prior authorization requirements, step therapy rules, and how to appeal a denial.
A framework for tapering off Lunesta (eszopiclone) after regular use, covering rebound insomnia, taper pacing, CBT-I bridging, and when to involve a prescriber. Pending qualified medical review.
A guide to eszopiclone food and supplement interactions, including alcohol, grapefruit, fatty meals, valerian, melatonin, CBD, and more.
Evidence-based guide to eszopiclone (Lunesta) dosing in older adults. Covers FDA-recommended starting doses, pharmacokinetic changes after 65, falls risk, CYP3A4 interactions, and deprescribing strategies.
Evidence-based guidance on what to do when you miss a dose of Lunesta (eszopiclone), including timing thresholds, rebound insomnia risks, and when to resume your normal schedule.
A clinician-grade review of eszopiclone (Lunesta) pharmacokinetics covering absorption, distribution, metabolism via CYP3A4/CYP2E1, and renal elimination, with dose-adjustment guidance for special populations.
Eszopiclone (Lunesta) is FDA-approved in the US but unavailable in Europe, Canada, and the UK, where the racemic parent compound zopiclone fills the same therapeutic niche. This article explains why.
A comprehensive clinical review of eszopiclone (Lunesta) safety signals, FDA regulatory actions, boxed warnings, dose reductions, and post-market surveillance findings with cited evidence.
A guide to Repatha (evolocumab) dosing for adults aged 30 to 49, covering FDA-approved schedules, injection technique, missed-dose handling, and what remains individualized versus standardized.
A clinical deep-dive into Repatha's manufacturing process, supply chain structure, and documented shortage events, with FDA-sourced evidence and clearly flagged areas needing verification.
Medicare Advantage plans cover Repatha (evolocumab) through Part D for familial hypercholesterolemia and established cardiovascular disease, but prior authorization and step therapy are near-universal hurdles. Here is what determines approval.
Evidence-based guide to switching between Repatha (evolocumab) and other PCSK9 inhibitors or lipid-lowering therapies, including alirocumab, inclisiran, bempedoic acid, and statins.
Planning to stop ezetimibe? Record the exact ingredient change, compare dated LDL results, and separate treatment response from cardiovascular benefit.
A physician-level explanation of how ezetimibe (Zetia) blocks intestinal cholesterol absorption through NPC1L1, lowers LDL-C, and complements statin therapy.
Evidence-based ezetimibe (Zetia) monitoring schedule covering lipid panels, liver function tests, CK levels, and follow-up exam timing. MD-level depth with PubMed and FDA citations.
Evidence-based guide to ezetimibe (Zetia) 10 mg dosing in adults aged 50-64, covering IMPROVE-IT trial data, polypharmacy considerations, statin combination therapy, and monitoring protocols.
Evidence-based guide to ezetimibe (Zetia) storage conditions, chemical stability, shelf life, and what to do if tablets are exposed to heat, light, or humidity.
A clinical review of finasteride safety data for men aged 30 to 49, covering sexual side effects, mental health signals, post-finasteride syndrome, liver and cardiovascular markers, and monitoring protocols.
How stopping finasteride differs for 1 mg hair loss and 5 mg BPH, including taper evidence, loss of benefit, PSA context, and current safety warnings.
Finasteride is not a blood thinner. It has no FDA-listed drug interactions, though it does cut PSA levels by about 50% and pairs safely with alpha-blockers.
Missed a finasteride dose? Don't double up. Take it the same day if you remember; if your next dose is close, skip it and resume your regular schedule.
Evidence-based finasteride monitoring schedule covering baseline labs, PSA adjustments, liver function, hormones, and follow-up exams for men on 1 mg or 5 mg finasteride.
A guide to finasteride's off-label applications beyond BPH and male pattern hair loss, with trial data and evidence grading for each use.
Finasteride's terminal half-life is 5 to 6 hours in men 18-60 (8+ hours over 70), but its effect on DHT lasts much longer due to irreversible enzyme binding.
Evidence-based monitoring protocol for finasteride in young adults aged 18 to 29, covering baseline labs, follow-up intervals, sexual side effects, mental health screening, and fertility planning.
A clinical breakdown of flibanserin (Addyi) pricing, generic availability, and how it compares in cost and efficacy to bremelanotide (Vyleesi) and off-label alternatives for HSDD.
Evidence-based guide to safely discontinuing flibanserin (Addyi), including taper considerations, timeline expectations, and what to discuss with your prescriber before stopping.
A guide to flibanserin (Addyi) food and supplement interactions, including alcohol, grapefruit, CYP3A4 inhibitors, and herbal products that alter drug levels.
Evidence-based guidance on what to do if you miss a dose of flibanserin (Addyi), including timing rules, safety precautions, and how skipping doses affects efficacy.
Complete pharmacokinetic profile of flibanserin (Addyi) including absorption, distribution, CYP3A4 metabolism, elimination half-life, food effects, and clinical implications for HSDD treatment.
Evidence-based guide to flibanserin (Addyi) dosing in patients with renal impairment, including pharmacokinetic data, FDA labeling, clinical trial evidence, and practical prescribing considerations.
Evidence-based guide to flibanserin use in special populations including organ transplant recipients, women living with HIV, those with hepatic impairment, and other complex clinical scenarios.
A clinical comparison of GHK-Cu pricing, efficacy, and mechanism against BPC-157, TB-500, and other tissue-repair peptides available through 503A compounding pharmacies.
A route-aware audit of GHK-Cu food and supplement claims, including zinc, copper, vitamin C, iron, meals, and the absence of validated spacing rules.
Evidence-based guidance on managing missed doses of GHK-Cu (copper tripeptide). Covers pharmacokinetics, half-life data, resumption timing, and when to contact your prescriber.
Evidence-based monitoring schedule for GHK-Cu (copper tripeptide) therapy, including recommended labs, exam intervals, copper levels, liver function, and safety benchmarks.
What to do after possible GHK-Cu excess exposure: emergency triage, Poison Control, product traceability, route, and copper-evidence limits.
MD-level review of GHK-Cu pharmacogenomics, copper transporter polymorphisms, collagen gene variants, and how genetic variability influences copper tripeptide efficacy for tissue repair and skin rejuvenation.
A clinician-grade breakdown of GHK-Cu regulatory status across the United States, European Union, Canada, and United Kingdom, covering FDA compounding rules, cosmetic classifications, and prescription access.
A guide to GHK-Cu (copper tripeptide) self-injection technique covering reconstitution, subcutaneous administration, dosing protocols, injection site rotation, and safety monitoring.
An evidence map for GHK-Cu in Wilson disease, liver or kidney disease, pregnancy, childhood, immunocompromise, transplant care, and cancer history.